Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.

Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Herve Avet-Loiseau, Tomer M Mark, Ivan Spicka, Alberto Bosi, Vania TM Hungria, Michele Cavo, Je-Jung Lee, Ajay K Nooka, Hang Quach, Markus Munder, Meral Beksac, Pieter Sonneveld, David Soong, Jon Ukropec, Ming Qi, Maria-Victoria Mateos